Oxidative stress signaling in Alzheimer's disease.

Multiple lines of evidence demonstrate that oxidative stress is an early event in Alzheimer's disease (AD), occurring prior to cytopathology, and therefore may play a key pathogenic role in AD. Oxidative stress not only temporally precedes the pathological lesions of the disease but also activates cell signaling pathways, which, in turn, contribute to lesion formation and, at the same time, provoke cellular responses such as compensatory upregulation of antioxidant enzymes found in vulnerable neurons in AD. In this review, we provide an overview of the evidence of oxidative stress and compensatory responses that occur in AD, particularly focused on potential sources of oxidative stress and the roles and mechanism of activation of stress-activated protein kinase pathways.

[1]  G. Perry,et al.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. , 1994, The American journal of pathology.

[2]  Yan‐Mei Li,et al.  Hydrogen peroxide can be generated by tau in the presence of Cu(II). , 2007, Biochemical and biophysical research communications.

[3]  N. Robakis,et al.  Immunohistochemical evidence of antioxidant stress in Alzheimer's disease , 1992 .

[4]  J. Baynes Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[5]  Xiongwei Zhu,et al.  Apoptosis in Alzheimer disease: a mathematical improbability. , 2006, Current Alzheimer research.

[6]  R. Swerdlow,et al.  Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture , 2004, Neurobiology of Disease.

[7]  Xiantao Wang,et al.  Signaling Events in Amyloid β-Peptide-induced Neuronal Death and Insulin-like Growth Factor I Protection* , 2002, The Journal of Biological Chemistry.

[8]  I. Ferrer,et al.  Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies , 2001, Journal of Neural Transmission.

[9]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[10]  R. Swerdlow,et al.  Abnormal Mitochondrial Morphology in Sporadic Parkinson's and Alzheimer's Disease Cybrid Cell Lines , 2000, Experimental Neurology.

[11]  George Perry,et al.  Role of mitochondrial dysfunction in Alzheimer's disease , 2002, Journal of neuroscience research.

[12]  P. Ince,et al.  Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD , 2001, Neurology.

[13]  Xiongwei Zhu,et al.  Activation and redistribution of c‐Jun N‐terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease , 2001, Journal of neurochemistry.

[14]  Hyoung-Gon Lee,et al.  Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.

[15]  W. Markesbery,et al.  Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Beal,et al.  Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[17]  W. D. Ehmann,et al.  Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease , 1995, Neurology.

[18]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[19]  S. Hazen,et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. , 1999, The Journal of clinical investigation.

[20]  J. Zweier,et al.  Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide , 1995, Nature Medicine.

[21]  D. Harman,et al.  The aging process. , 1981, Basic life sciences.

[22]  C. Behl,et al.  Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.

[23]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[24]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[25]  T. Arendt,et al.  Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation , 2002, Brain Research.

[26]  Xudong Huang,et al.  Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). , 2002, The Journal of biological chemistry.

[27]  Y. Surh,et al.  β‐Amyloid Induces Oxidative DNA Damage and Cell Death through Activation of c‐Jun N Terminal Kinase , 2002 .

[28]  Robert B. Petersen,et al.  Mitochondrial abnormalities in Alzheimer disease , 2000, Neurobiology of Aging.

[29]  George Perry,et al.  Activation of p38 Kinase Links Tau Phosphorylation, Oxidative Stress, and Cell Cycle‐Related Events in Alzheimer Disease , 2000 .

[30]  R. Veerhuis,et al.  The role of complement and activated microglia in the pathogenesis of Alzheimer's disease , 1996, Neurobiology of Aging.

[31]  W. Markesbery,et al.  p38 Kinase Is Activated in the Alzheimer's Disease Brain , 1999, Journal of neurochemistry.

[32]  George Perry,et al.  Physiological regulation of tau phosphorylation during hibernation , 2008, Journal of neurochemistry.

[33]  M. Soriani,et al.  Antioxidant potential of anaerobic human plasma: role of serum albumin and thiols as scavengers of carbon radicals. , 1994, Archives of biochemistry and biophysics.

[34]  W. Markesbery,et al.  The Nitration Product 5-Nitro-γ-tocopherol Is Increased in the Alzheimer Brain , 2002 .

[35]  Huaxi Xu,et al.  Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimer's neurodegeneration , 2007, Proceedings of the National Academy of Sciences.

[36]  A. Palmer,et al.  Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease , 1994, Brain Research.

[37]  I. Kanazawa,et al.  JNK activation is associated with intracellular β-amyloid accumulation , 2000 .

[38]  H. Möller,et al.  A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients , 2000, Neurobiology of Aging.

[39]  M. Beal,et al.  Cytochemical Demonstration of Oxidative Damage in Alzheimer Disease by Immunochemical Enhancement of the Carbonyl Reaction with 2,4-Dinitrophenylhydrazine , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[40]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[41]  C. Velez-Pardo,et al.  Aβ[25–35] Peptide and Iron Promote Apoptosis in Lymphocytes by an Oxidative Stress Mechanism: Involvement of H2O2, Caspase-3, NF-κB, p53 and c-Jun , 2002 .

[42]  M. Smith,et al.  Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? , 1999, Free radical biology & medicine.

[43]  R. Veerhuis,et al.  Amyloid β Protein Primes Cultured Rat Microglial Cells for an Enhanced Phorbol 12‐Myristate 13‐Acetate‐Induced Respiratory Burst Activity , 1996, Journal of neurochemistry.

[44]  Xiongwei Zhu,et al.  Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. , 2004, Journal of Alzheimer's disease : JAD.

[45]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[46]  Xiongwei Zhu,et al.  Ribosomal RNA in Alzheimer Disease Is Oxidized by Bound Redox-active Iron* , 2005, Journal of Biological Chemistry.

[47]  George Perry,et al.  RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[48]  W. Blackstock,et al.  Phosphorylation Sites on Tau Identified by Nanoelectrospray Mass Spectrometry , 2000, Journal of neurochemistry.

[49]  G. Perry,et al.  Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. , 2000, Antioxidants & redox signaling.

[50]  D. Perl,et al.  Evidence of neuronal oxidative damage in Alzheimer's disease. , 1996, The American journal of pathology.

[51]  P. Mcgeer,et al.  β‐Amyloid protein enhances macrophage production of oxygen free radicals and glutamate , 1997 .

[52]  Ying-Hua Liu,et al.  Peroxynitrite induces Alzheimer‐like tau modifications and accumulation in rat brain and its underlying mechanisms , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  D. Galati,et al.  Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.

[54]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[55]  L. Greene,et al.  β‐Amyloid‐induced neuronal apoptosis requires c‐Jun N‐terminal kinase activation , 2001, Journal of neurochemistry.

[56]  A. Kontush,et al.  Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer’s disease , 2001 .

[57]  D. Butterfield,et al.  Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. , 2000, Journal of structural biology.

[58]  B. P. Yu,et al.  Cellular defenses against damage from reactive oxygen species. , 1994, Physiological reviews.

[59]  B. Winblad,et al.  Acute anoxia induces tau dephosphorylation in rat brain slices and its possible underlying mechanisms , 2005, Journal of neurochemistry.

[60]  L. Iversen,et al.  The toxicity in vitro of beta-amyloid protein. , 1995, The Biochemical journal.

[61]  S. Bondy,et al.  Promotion of transition metal-induced reactive oxygen species formation by β-amyloid , 1998, Brain Research.

[62]  D. Butterfield,et al.  Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. , 2001, Trends in molecular medicine.

[63]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[64]  S Shimohama,et al.  Activation of MKK6, an upstream activator of p38, in Alzheimer's disease , 2001, Journal of neurochemistry.

[65]  J. Quinn,et al.  Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. , 2004, Human molecular genetics.

[66]  Mark A. Smith,et al.  Advanced Maillard Reaction End Products, Free Radicals, and Protein Oxidation in Alzheimer's Disease a , 1994, Annals of the New York Academy of Sciences.

[67]  D. Butterfield,et al.  Alzheimer’s amyloid β-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide , 2004, Neurobiology of Aging.

[68]  J. Crowley,et al.  The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. , 1999, The Journal of clinical investigation.

[69]  M. Beal,et al.  Oxidative damage in Alzheimer's , 1996, Nature.

[70]  P. Lewitt,et al.  Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders , 1996, Brain Research.

[71]  J. Thome,et al.  Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's disease. , 1996, Life sciences.

[72]  D. Bozyczko‐Coyne,et al.  CEP‐1347/KT‐7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Aβ‐induced cortical neuron apoptosis , 2001, Journal of neurochemistry.

[73]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[74]  M. Mattson,et al.  A Role for 4‐Hydroxynonenal, an Aldehydic Product of Lipid Peroxidation, in Disruption of Ion Homeostasis and Neuronal Death Induced by Amyloid β‐Peptide , 1997, Journal of neurochemistry.

[75]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[76]  J. Thome,et al.  Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.

[77]  S. Tsuji,et al.  Apolipoprotein E allele–dependent antioxidant activity in brains with Alzheimer’s disease , 2000, Neurology.

[78]  H. Qing,et al.  Oxidative stress potentiates BACE1 gene expression and Aβ generation , 2005, Journal of Neural Transmission.

[79]  Jack C. de la Torre,et al.  Cerebromicrovascular Pathology in Alzheimer’s Disease Compared to Normal Aging , 1997 .

[80]  B. Anderton,et al.  Stress‐Activated Protein Kinase/c‐Jun N‐Terminal Kinase Phosphorylates τ Protein , 1997, Journal of neurochemistry.

[81]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  J. Blass,et al.  Abnormalities of mitochondrial enzymes in Alzheimer disease , 1998, Journal of Neural Transmission.

[83]  R J Mark,et al.  Amyloid β-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation , 1997, The Journal of Neuroscience.

[84]  J. D. Robertson,et al.  Copper, iron and zinc in Alzheimer's disease senile plaques , 1998, Journal of the Neurological Sciences.

[85]  J. Joseph,et al.  The state versus amyloid-β: the trial of the most wanted criminal in Alzheimer disease , 2002, Peptides.

[86]  G. Perry,et al.  β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways , 2005, Journal of neurochemistry.

[87]  B. Ghetti,et al.  Activation of the JNK/p38 Pathway Occurs in Diseases Characterized by Tau Protein Pathology and Is Related to Tau Phosphorylation But Not to Apoptosis , 2001, Journal of neuropathology and experimental neurology.

[88]  C. Colaco,et al.  A glycation connection , 1994, Nature.

[89]  Visith Thongboonkerd,et al.  Proteomic identification of nitrated proteins in Alzheimer's disease brain , 2003, Journal of neurochemistry.

[90]  A. Nebreda,et al.  Reactivating Kinase/p38 Phosphorylates τ Protein In Vitro , 1997 .

[91]  Fahmeed Hyder,et al.  Energetic basis of brain activity: implications for neuroimaging , 2004, Trends in Neurosciences.

[92]  Xiongwei Zhu,et al.  Mitochondrial failures in Alzheimer's disease , 2004, American journal of Alzheimer's disease and other dementias.

[93]  Xiongwei Zhu,et al.  Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.

[94]  M. Wajner,et al.  Impairment of energy metabolism in hippocampus of rats subjected to chemically-induced hyperhomocysteinemia. , 2003, Biochimica et biophysica acta.

[95]  D. Schubert,et al.  The role of iron in beta amyloid toxicity. , 1995, Biochemical and biophysical research communications.

[96]  C. W. Scott,et al.  Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[97]  B. Hyman,et al.  Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function , 2005, Science.

[98]  M. Mattson,et al.  Oxidative stress activates a positive feedback between the γ‐ and β‐secretase cleavages of the β‐amyloid precursor protein , 2007 .

[99]  H. Reichmann,et al.  Electron transport chain defects in Alzheimer's disease. , 1994, Neurology.

[100]  M. Smith,et al.  Neuronal RNA Oxidation in Alzheimer's Disease and Down's Syndrome , 1999, Annals of the New York Academy of Sciences.

[101]  P. Lantos,et al.  Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. , 1999, Journal of neuropathology and experimental neurology.

[102]  J. Loike,et al.  Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.

[103]  S. Rapoport,et al.  Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. , 1994, Brain research. Molecular brain research.

[104]  Ashley I. Bush,et al.  Redox-active iron mediates amyloid-β toxicity , 2001 .

[105]  B. Frei,et al.  Physiological thiol compounds exert pro- and anti-oxidant effects, respectively, on iron- and copper-dependent oxidation of human low-density lipoprotein. , 1997, Biochimica et biophysica acta.

[106]  M. Greenberg,et al.  β-Amyloid Induces Neuronal Apoptosis Via a Mechanism that Involves the c-Jun N-Terminal Kinase Pathway and the Induction of Fas Ligand , 2001, The Journal of Neuroscience.

[107]  E. Masliah,et al.  Myeloperoxidase Polymorphism Is Associated with Gender Specific Risk for Alzheimer's Disease , 1999, Experimental Neurology.

[108]  M. Esiri,et al.  Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology , 1999, Acta Neuropathologica.

[109]  S. Arlt,et al.  Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma , 2001 .

[110]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[111]  Xiongwei Zhu,et al.  JKK1, an upstream activator of JNK/SAPK, is activated in Alzheimer's disease , 2003, Journal of neurochemistry.

[112]  R. Mrak,et al.  Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease , 1996, Journal of neuropathology and experimental neurology.

[113]  M. Goldberg,et al.  Amyloid-β Peptides Are Cytotoxic to Oligodendrocytes , 2001, The Journal of Neuroscience.

[114]  M. Beal,et al.  Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. , 2008, Trends in molecular medicine.

[115]  W. Markesbery,et al.  Four-Hydroxynonenal, a Product of Lipid Peroxidation, is Increased in the Brain in Alzheimer’s Disease , 1998, Neurobiology of Aging.

[116]  Philip R. Cohen,et al.  Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases , 1997, FEBS letters.

[117]  Hyoung-Gon Lee,et al.  Tau phosphorylation in Alzheimer's disease: pathogen or protector? , 2005, Trends in molecular medicine.

[118]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[119]  Jason P. Sheehan,et al.  Calcium Homeostasis and Reactive Oxygen Species Production in Cells Transformed by Mitochondria from Individuals with Sporadic Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[120]  L. Mucke,et al.  Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[121]  H. Braak,et al.  Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. , 2001, Journal of Alzheimer's disease : JAD.

[122]  Xiongwei Zhu,et al.  c‐Jun phosphorylation in Alzheimer disease , 2007, Journal of neuroscience research.

[123]  Mark A. Smith,et al.  Carbonyl‐Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease , 1995, Journal of neurochemistry.

[124]  R. Mason,et al.  Alzheimer's disease amyloid beta peptide 25-35 inhibits lipid peroxidation as a result of its membrane interactions. , 1997, Biochemical and biophysical research communications.

[125]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[126]  D. Flood,et al.  Activation of c-Jun N-Terminal Kinase and p38 in an Alzheimer's Disease Model Is Associated with Amyloid Deposition , 2002, The Journal of Neuroscience.

[127]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[128]  G. Perry,et al.  Involvement of maillard reactions in Alzheimer disease , 2009, Neurotoxicity Research.

[129]  R N Kalaria,et al.  Induction of Heme Oxygenase‐1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease , 1995, Journal of neurochemistry.

[130]  C. Filley,et al.  Reduced platelet cytochrome c oxidase activity in Alzheimer's disease , 1994, Neurology.

[131]  M. Staufenbiel,et al.  Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer’s disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology , 2001, Brain Research.

[132]  G. Perry,et al.  Neuronal Oxidative Stress Precedes Amyloid‐β Deposition in Down Syndrome , 2000 .